Purpose

Atropine eye drops are a common and effective treatment for slowing myopia progression, but the site and mode of action of atropine in controlling myopia are unclear. We investigated the early retinal sites of action of atropine by examining its effects on the human full-field electroretinogram (ffERG).

Method

Baseline ffERGs were recorded in both eyes of 24 healthy subjects (mean ± SD: 21.0 ± 2.3 years; spherical equivalent refraction, range: + 1.63 to − 0.75 D) using 6 standard ISCEV protocols, 30 min after bilateral pupil dilation with 1% Tropicamide. Atropine (1 drop, 0.1%) was then instilled into the non-dominant eye. 24 h later, ffERGs were again recorded in both eyes. Ratios (post-atropine: pre-atropine) of dark-adapted (DA) and light-adapted (LA) ffERGs were compared between atropine-treated and control eyes using multivariate repeated measures general linear models.

Results

Atropine-treated eyes responded with 14% lower DA3.0 OP (oscillatory potential) amplitude (p = 0.003) and 4% delay in the DA10.0 a-wave peak time (p = 0.00099) compared with control eyes. Amplitudes and peak times were not different between atropine-treated and control eyes for DA0.01, LA3.0, and LA3.0 flicker ERGs. While atropine caused a small (1.26 mm², p = 0.03) extra increase in pupil area in the treated eye, atropine-induced changes in ffERG responses bore no relationship with changes in pupil area (R²= 2–5%, p > 0.05).

Conclusions

The observed changes in oscillatory potentials corroborate previous findings that atropine affects neural activity in the inner retina. However, observed changes to the a-wave suggest that atropine also affects activity in photoreceptors.

中文翻译：

---

阿托品滴眼液对人全视野视网膜电图的急性作用

目的

阿托品滴眼液是一种常见且有效的减缓近视进展的治疗方法，但阿托品控制近视的部位和作用方式尚不清楚。我们通过检查阿托品对人类全视野视网膜电图 (ffERG) 的影响，研究了阿托品的早期视网膜作用部位。

方法

使用 6 种标准 ISCEV 协议，在双侧瞳孔扩张后 30 分钟，使用 1% 托吡卡胺进行双侧瞳孔扩张后，在 24 名健康受试者的双眼中记录基线 ffERG（平均±标准差：21.0±2.3 岁；球面等效屈光度，范围：+ 1.63 至 - 0.75 D） . 然后将阿托品（1 滴，0.1%）滴入非优势眼。24 小时后，再次在双眼中记录了 ffERG。使用多元重复测量一般线性模型比较阿托品治疗眼和对照眼之间的暗适应 (DA) 和光适应 (LA) ffERG 的比率（阿托品后：阿托品前）。

结果

与对照眼相比，阿托品治疗眼的 DA3.0 OP（振荡电位）幅度降低 14%（p  = 0.003），DA10.0 a 波峰值时间延迟 4%（p  = 0.00099）。对于 DA0.01、LA3.0 和 LA3.0 闪烁 ERG，阿托品治疗眼和对照眼的振幅和峰值时间没有差异。虽然阿托品导致 治疗眼瞳孔面积小幅（1.26 mm ²，p = 0.03）额外增加，但阿托品引起的 ffERG 反应变化与瞳孔面积变化无关（R ² = 2–5%，p  > 0.05）。

结论

观察到的振荡电位变化证实了先前的发现，即阿托品影响内视网膜的神经活动。然而，观察到的 a 波变化表明阿托品也会影响光感受器的活动。